Molecular networks in drug discovery

Critical Reviews in Biomedical Engineering

Volumn 38, Issue 2, 2010, Pages 143-156

  Morrow, John Kenneth ^a   Tian, Longzhang ^a   Zhang, Shuxing ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Drug discovery; In silico prediction; Molecular networks; Polypharmacology

Indexed keywords

DRUG INTERACTIONS; FORECASTING; TOXICITY;

ADVERSE DRUG REACTIONS; DRUG DEVELOPMENT; DRUG DISCOVERY; FUNDAMENTAL CONCEPTS; IN-SILICO; MOLECULAR NETWORKS; MULTIPLE TARGETS; POLYPHARMACOLOGY;

DRUG PRODUCTS;

ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; CISPLATIN; CLOZAPINE; DASATINIB; DELAVIRDINE; DOPAMINE RECEPTOR; EPHRIN RECEPTOR A2; FLUOXETINE; HISTAMINE H4 RECEPTOR; IMATINIB; LIGAND; MUSCARINIC RECEPTOR; PAROXETINE; PP 121; PP121; PREDNISOLONE; PROTEIN KINASE; PROTEIN P110; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP; QUERCETIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANAMIVIR;

ACNE; ALZHEIMER DISEASE; BINDING AFFINITY; CEREBROVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; DEPRESSION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DEVELOPMENT; GASTROINTESTINAL STROMAL TUMOR; HEART DISEASE; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTENSION; HYPOTENSION; INFECTIOUS DISEASE MEDICINE; INHALER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MOOD DISORDER; NEOPLASM; PHARMACEUTICAL ENGINEERING; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SCHIZOPHRENIA;

EID: 78650163943     PISSN: 0278940X     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevBiomedEng.v38.i2.30     Document Type: Review

References (96)

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003 Mar;22(2):151-85.
2. Martinez B, Goldstein J. Big pharma faces grim prognosis. Wall Street J. 2007 Dec 6. p. A1.
3. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004 Aug;3(8):711-5.
4. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics. 2002;20(Suppl 3):1-10.
5. Janga SC, Tzakos A. Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. Mol Biosyst. 2009 Dec;5:1536-48.
6. Collier R. Drug development cost estimates hard to swallow. CMAJ. 2009 Feb 3;180(3):279-80.
7. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008 Nov;4(11):682-90.
8. Ma P, Zemmel R. Value of novelty? Nat Rev Drug Discov. 2002 Aug;1(8):571-2.
9. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
10. Wagner A. Robustness against mutations in genetic networks of yeast. Nat Genet. 2000 Apr;24(4):355-61. (Pubitemid 30187432)
11. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. Drug-target network. Nat Biotechnol. 2007 Oct;25(10):1119-26.
12. Zambrowicz BP. Modeling drug action in the mouse with knockouts and RNA interference. Drug Discov Today: Targets. 2004;3(5):198-207.
13. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, Bangham R, Benito R, Boeke JD, Bussey H, Chu AM, Connelly C, Davis K, Dietrich F, Dow SW, El Bakkoury M, Foury F, Friend SH, Gentalen E, Giaever G, Hegemann JH, Jones T, Laub M, Liao H, Liebundguth N, Lockhart DJ, Lucau-Danila A, Lussier M, M'Rabet N, Menard P, Mittmann M, Pai C, Rebischung C, Revuelta JL, Riles L, Roberts CJ, Ross-MacDonald P, Scherens B, Snyder M, Sookhai-Mahadeo S, Storms RK, Véronneau S, Voet M, Volckaert G, Ward TR, Wysocki R, Yen GS, Yu K, Zimmermann K, Philippsen P, Johnston M, Davis RW. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science. 1999 Aug 6;285(5429):901-6.
14. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002 Sep;1(9):727-30.
15. Austin CP, Battey JF, Bradley A, Bucan M, Capecchi M, Collins FS, Dove WF, Duyk G, Dymecki S, Eppig JT, Grieder FB, Heintz N, Hicks G, Insel TR, Joyner A, Koller BH, Lloyd KC, Magnuson T, Moore MW, Nagy A, Pollock JD, Roses AD, Sands AT, Seed B, Skarnes WC, Snoddy J, Soriano P, Stewart DJ, Stewart F, Stillman B, Varmus H, Varticovski L, Verma IM, Vogt TF, von Melchner H, Witkowski J, Woychik RP, Wurst W, Yancopoulos GD, Young SG, Zambrowicz B.. The knockout mouse project. Nat Genet. 2004 Sep;36(9):921-4.
16. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol. 2003 Oct;3(5):563-70.
17. Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet. 2004 Feb;5(2):101-13.
18. Kitano H. Towards a theory of biological robustness. Mol Syst Biol. 2007;3:137.
19. Hartman JL, Garvik B, Hartwell L. Principles for the buffering of genetic variation. Science. 2001 Feb 9;291(5506):1001-4.
20. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci. 2005 Apr;26(4):178-82.
21. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today. 2005 Jan 15;10(2):139-47.
22. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep. 2009 Apr 17;57(14):1-134.
23. Varmus H. The new era in cancer research. Science. 2006 May 26;312(5777):1162-5.
24. Booth B, Glassman R, Ma P. Oncology's trials. Nat Rev Drug Discov. 2003 Aug;2(8):609-10.
25. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001 May 17;411(6835):355-65.
26. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005 Jul 14;353(2):172-87.
27. Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules. Nature. 2006 May 25;441(7092):457-62.
28. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 2008;15(5):422-32. (Pubitemid 351472408)
29. Walker I, Newell H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov. 2009 Jan;8(1):15-6.
30. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006 May 25;441(7092):424-30.
31. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004 Apr 23;304(5670):554. (Pubitemid 38541907)
32. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004 Oct;3(10):1221-4. (Pubitemid 40268595)
33. Akritopoulou-Zanze I, Hajduk PJ. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov Today. 2009 Mar;14(5-6):291-7.
34. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
35. Snyder EM, Murphy MR. Schizophrenia therapy: beyond atypical antipsychotics. Nat Rev Drug Discov. 2008 Jun;7(6):471-2.
36. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004 Apr;3(4):353-9.
37. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, Schwab SG, Pulver AE, Faraone SV, Brzustowicz LM, Kaufmann CA, Garver DL, Gurling HM, Lindholm E, Coon H, Moises HW, Byerley W, Shaw SH, Mesen A, Sherrington R, O'Neill FA, Walsh D, Kendler KS, Ekelund J, Paunio T, Lönnqvist J, Peltonen L, O'Donovan MC, Owen MJ, Wildenauer DB, Maier W, Nestadt G, Blouin JL, Antonarakis SE, Mowry BJ, Silverman JM, Crowe RR, Cloninger CR, Tsuang MT, Malaspina D, Harkavy-Friedman JM, Svrakic DM, Bassett AS, Holcomb J, Kalsi G, McQuillin A, Brynjolfson J, Sigmundsson T, Petursson H, Jazin E, Zoëga T, Helgason T. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet. 2003 Jul;73(1):34-48. (Pubitemid 36793778)
38. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet. 2003 Feb 1;361(9355):417-9.
39. Bianchi MT. Promiscuous modulation of ion channels by anti-psychotic and anti-dementia medications. Med Hypotheses. 2010 Feb;74(2):297-300
40. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 Sep;45(9):789-96.
41. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S; International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003 Jan;60(1):82-91.
42. Zubenko GS, Maher B, Hughes HB 3rd, Zubenko WN, Stiffler JS, Kaplan BB, Marazita ML. Genome-wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early-onset, major depression. Am J Med Genet B Neuropsychiatr Genet. 2003 Nov 15;123B(1):1-18.
43. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull. 2001;57:161-78.
44. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001 Mar;178:234-41.
45. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov. 2006 Aug;5(8):649-59.
46. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol. 2006 Jul;24(7):805-15.
47. Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics. 2008 Jul 1;24(13):i232-40.
48. Jacob L, Vert JP. Protein-ligand interaction prediction: an improved chemogenomics approach. Bioinformatics. 2008 Oct 1;24(19):2149-56.
49. Brewerton SC. The use of protein-ligand interaction fingerprints in docking. Curr Opin Drug Discov Devel. 2008 May;11(3):356-64.
50. Hillenmeyer ME, Fung E, Wildenhain J, Pierce SE, Hoon S, Lee W, Proctor M, St Onge RP, Tyers M, Koller D, Altman RB, Davis RW, Nislow C, Giaever G. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science. 2008 Apr 18;320(5874):362-5.
51. Kuhn M, Campillos M, Gonzalez P, Jensen LJ, Bork P. Large-scale prediction of drug-target relationships. FEBS Lett. 2008 Apr 9;582(8):1283-90.
52. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. DrugBank: a knowledge-base for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
53. The PubChem Project; 2010. http://pubchem.ncbi.nlm.nih.gov (accessed 2010 Aug 12).
54. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
55. Hu L, Benson ML, Smith RD, Lerner MG, Carlson HA. Binding MOAD (mother of all databases). Proteins. 2005 Aug 15;60(3):333-40.
56. ChEMBL Database; 2010. http://www.ebi.ac.uk/chembl/ (accessed 2010 Aug 12).
57. Irwin JJ, Shoichet BK. ZINC - a free database of commercially available compounds for virtual screening. Chem Inf Model. 2005 Jan-Feb;45(1):177-82.
58. Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. 2008 Jan;36(Database issue):D684-8. (Pubitemid 351149807)
59. Kuhn M, Szklarczyk D, Franceschini A, Campillos M, von Mering C, Jensen LJ, Beyer A, Bork P. STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res. 2010 Jan;38(Database issue):D552-6.
60. Berg EL, Kunkel EJ, Hytopoulos E. Biological complexity and drug discovery: a practical systems biology approach. Syst Biol (Stevenage). 2005 Dec;152(4):201-6. (Pubitemid 43125137)
61. Boyle J, Cavnor C, Killcoyne S, Shmulevich I. Systems biology driven software design for the research enterprise. BMC Bioinformatics. 2008;9:295.
62. Mayburd AL, Martlinez A, Sackett D, Liu H, Shih J, Tauler J, Avis I, Mulshine JL. Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886. Clin Cancer Res. 2006 Mar 15;12(6):1820-7.
63. Splendiani A. RDFScape: Semantic Web meets systems biology. BMC Bioinformatics. 2008;9(Suppl 4):S6.
64. Steinhauser D, Usadel B, Luedemann A, Thimm O, Kopka J. CSB.DB: a comprehensive systems-biology database. Bioinformatics. 2004 Dec 12;20(18):3647-51.
65. Wierling C, Herwig R, Lehrach H. Resources, standards and tools for systems biology. Brief Funct Genomic Proteomic. 2007 Sep;6(3):240-51. (Pubitemid 351863879)
66. Schreiber SL. Small molecules: the missing link in the central dogma. Nat Chem Biol. 2005 Jul;1(2):64-6.
67. Johnson MA, Maggiora GM. Concepts and applications of molecular similarity. Hoboken, NJ: Wiley; 1990.
68. Whittle M, Gillet VJ, Willett P, Alex A, Loesel J. Enhancing the effectiveness of virtual screening by fusing nearest neighbor lists: a comparison of similarity coefficients. J Chem Inf Comput Sci. 2004 Sep-Oct;44(5):1840-8.
69. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta. 2004 Mar 11;1697(1-2):243-57.
70. Izrailev S, Farnum MA. Enzyme classification by ligand binding. Proteins. 2004 Dec 1;57(4):711-24.
71. Hert J, Keiser MJ, Irwin JJ, Oprea TI, Shoichet BK. Quantifying the relationships among drug classes. J Chem Inf Model. 2008 Apr;48(4):755-65.
72. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007 Feb;25(2):197-206. (Pubitemid 46227119)
73. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL. Predicting new molecular targets for known drugs. Nature. 2009 Nov 12;462(7270):175-81.
74. Fliri AF, Loging WT, Thadeio PF, Volkmann RA. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat Chem Biol. 2005 Dec;1(7):389-97.
75. Fliri AF, Loging WT, Volkmann RA. Analysis of system structure-function relationships. ChemMedChem. 2007 Dec;2(12):1774-82.
76. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008 Jul 11;321(5886):263-6. (Pubitemid 351989100)
77. Scheiber J, Chen B, Milik M, Sukuru SC, Bender A, Mikhailov D, Whitebread S, Hamon J, Azzaoui K, Urban L, Glick M, Davies JW, Jenkins JL. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J Chem Inf Model. 2009 Jan 13 [Epub ahead of print].
78. Tian L, Zhang S. Mapping drug-target interaction networks. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:2336-9.
79. Zhang S, Golbraikh A, Tropsha A. Development of quantitative structure-binding affinity relationship models based on novel geometrical chemical descriptors of the protein-ligand interfaces. J Med Chem. 2006 May 4;49(9):2713-24.
80. Zhang S, Golbraikh A, Oloff S, Kohn H, Tropsha A. A novel automated lazy learning QSAR (ALL-QSAR) approach: method development, applications, and virtual screening of chemical databases using validated ALL-QSAR models. J Chem Inf Model. 2006 Sep-Oct;46(5):1984-95.
81. Zhang S, Kumar K, Jiang X, Wallqvist A, Reifman J. DOVIS: an implementation for high-throughput virtual screening using AutoDock. BMC Bioinformatics. 2008;9:126.
82. Zhang S, Du-Cuny L. Development and evaluation of a new statistical model for structure-based high-throughput virtual screening. Int J Bioinform Res Appl. 2009;5(3):269-79.
83. Zhang S, Wei L, Bastow K, Zheng W, Brossi A, Lee KH, Tropsha A. Antitumor agents 252. Application of validated QSAR models to database mining: discovery of novel tylophorine derivatives as potential anticancer agents. J Comput Aided Mol Des. 2007 Jan-Mar;21(1-3):97-112.
84. Winger JA, Hantschel O, Superti-Furga G, Kuriyan J. The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct Biol. 2009;9:7.
85. O'Connor KA, Roth BL. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov. 2005 Dec;4(12):1005-14.
86. Uliana SR, Barcinski MA. Repurposing for neglected diseases. Science. 2009 Nov 13;326(5955):935; author reply.
87. Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. Science. 2009 Jun 12;324(5933):1394-5.
88. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet. 2009 Apr 11;373(9671):1301-9.
89. Wermuth CG. Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004 Mar 11;47(6):1303-14.
90. Wermuth CG. Selective optimization of side activities: the SOSA approach. Drug Discov Today. 2006 Feb;11(3-4):160-4.
91. Radhakrishnan ML, Tidor B. Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems. J Chem Inf Model. 2008 May;48(5):1055-73.
92. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. 2005 Jan;4(1):71-8.
93. Foungbe S, Kouassi G, Kablan JB, Marcy R. Study of Costus lucanusianus: plant juice, fraction combinations and pharmacologic estimation of natural product total activity. J Ethnopharmacol. 1991 Jul;33(3):221-6.
94. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003 Jul;112(1):29-36.
95. Wren JD, Bekeredjian R, Stewart JA, Shohet RV, Garner HR. Knowledge discovery by automated identification and ranking of implicit relationships. Bioinformatics. 2004 Feb 12;20(3):389-98.
96. Wermuth CG. Multitargeted drugs: the end of the "one-target-one- disease" philosophy? Drug Discov Today. 2004 Oct 1;9(19):826-7.